Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.09
-0.3067-0.74%
Volume:29.56K
Turnover:1.22M
Market Cap:1.06B
PE:- -
High:41.29
Open:41.29
Low:41.01
Close:41.40
52wk High:42.87
52wk Low:27.30
Shares:25.75M
Float Shares:25.75M
Volume Ratio:1.37
T/O Rate:0.11%
Dividend:0.42
Dividend Rate:1.03%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
8 hours ago

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Yesterday

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19

AbbVie presents new Vraylar data at Psych Congress 2026

TIPRANKS
·
Sep 18

AbbVie Says Real-World Studies Show Vraylar Improves Symptoms in MDD, Bipolar I Depression

Reuters
·
Sep 18

Bloomsbury Publishing (BMY) Gets a Buy from Berenberg Bank

TIPRANKS
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Bristol Myers Squibb to Report Q3 Results, Host Earnings Call

Reuters
·
Sep 18

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

THOMSON REUTERS
·
Sep 18

Merck Says EU CHMP Backs Keytruda-Padcev Perioperative Use in Resectable Muscle-Invasive Bladder Cancer

Reuters
·
Sep 18

Merck & Co - Final Ec Decision Expected by Q4 2026

THOMSON REUTERS
·
Sep 18

Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv) as Perioperative Treatment for Adults with Resectable Muscle-Invasive Bladder Cancer (Mibc)

THOMSON REUTERS
·
Sep 18

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living with Hiv

THOMSON REUTERS
·
Sep 18

All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan

Reuters
·
Sep 18